Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: ARHGAP18

Gene summary for ARHGAP18

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

ARHGAP18

Gene ID

93663

Gene nameRho GTPase activating protein 18
Gene AliasMacGAP
Cytomap6q22.33
Gene Typeprotein-coding
GO ID

GO:0000902

UniProtAcc

Q8N392


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
93663ARHGAP18CCI_2HumanCervixCC1.13e-02-5.70e-010.5249
93663ARHGAP18CCII_1HumanCervixCC1.59e-07-5.69e-010.3249
93663ARHGAP18TumorHumanCervixCC8.74e-23-5.69e-010.1241
93663ARHGAP18sample1HumanCervixCC4.22e-05-5.54e-010.0959
93663ARHGAP18sample3HumanCervixCC8.80e-23-5.60e-010.1387
93663ARHGAP18H2HumanCervixHSIL_HPV9.89e-13-5.01e-010.0632
93663ARHGAP18L1HumanCervixCC1.34e-06-5.37e-010.0802
93663ARHGAP18T1HumanCervixCC6.68e-08-4.86e-010.0918
93663ARHGAP18T3HumanCervixCC3.01e-21-5.77e-010.1389
93663ARHGAP18LZE4THumanEsophagusESCC3.37e-041.25e-010.0811
93663ARHGAP18LZE5THumanEsophagusESCC3.25e-045.37e-010.0514
93663ARHGAP18LZE24THumanEsophagusESCC4.42e-051.44e-010.0596
93663ARHGAP18LZE6THumanEsophagusESCC1.21e-022.03e-010.0845
93663ARHGAP18P2T-EHumanEsophagusESCC8.24e-092.22e-010.1177
93663ARHGAP18P4T-EHumanEsophagusESCC1.22e-037.49e-020.1323
93663ARHGAP18P5T-EHumanEsophagusESCC2.05e-035.25e-030.1327
93663ARHGAP18P8T-EHumanEsophagusESCC2.20e-378.67e-010.0889
93663ARHGAP18P10T-EHumanEsophagusESCC1.90e-111.67e-010.116
93663ARHGAP18P12T-EHumanEsophagusESCC3.68e-051.28e-010.1122
93663ARHGAP18P15T-EHumanEsophagusESCC1.65e-051.39e-010.1149
Page: 1 2 3 4 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
CervixThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.CC: Cervix cancer
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
N_HPV: HPV-infected normal cervix
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:000836024Oral cavityEOLPregulation of cell shape37/2218154/187231.80e-052.90e-0437
GO:00510569Oral cavityEOLPregulation of small GTPase mediated signal transduction51/2218302/187235.67e-032.92e-0251
GO:190290334Oral cavityNEOLPregulation of supramolecular fiber organization88/2005383/187232.44e-124.83e-1088
GO:004325432Oral cavityNEOLPregulation of protein-containing complex assembly95/2005428/187232.76e-125.29e-1095
GO:000701534Oral cavityNEOLPactin filament organization94/2005442/187234.49e-115.80e-0994
GO:003297033Oral cavityNEOLPregulation of actin filament-based process85/2005397/187232.70e-102.51e-0885
GO:003295633Oral cavityNEOLPregulation of actin cytoskeleton organization77/2005358/187231.51e-091.02e-0777
GO:003227133Oral cavityNEOLPregulation of protein polymerization57/2005233/187231.54e-091.03e-0757
GO:002260433Oral cavityNEOLPregulation of cell morphogenesis69/2005309/187232.07e-091.29e-0769
GO:005125833Oral cavityNEOLPprotein polymerization67/2005297/187232.27e-091.40e-0767
GO:000836033Oral cavityNEOLPregulation of cell shape41/2005154/187232.35e-081.03e-0641
GO:011005333Oral cavityNEOLPregulation of actin filament organization60/2005278/187238.37e-083.17e-0660
GO:003253532Oral cavityNEOLPregulation of cellular component size73/2005383/187236.70e-071.93e-0573
GO:000815431Oral cavityNEOLPactin polymerization or depolymerization47/2005218/187232.11e-064.91e-0547
GO:000806432Oral cavityNEOLPregulation of actin polymerization or depolymerization41/2005188/187236.83e-061.36e-0441
GO:003083232Oral cavityNEOLPregulation of actin filament length41/2005189/187237.83e-061.54e-0441
GO:003004132Oral cavityNEOLPactin filament polymerization41/2005191/187231.03e-051.94e-0441
GO:003083332Oral cavityNEOLPregulation of actin filament polymerization38/2005172/187231.07e-051.98e-0438
GO:005105614Oral cavityNEOLPregulation of small GTPase mediated signal transduction49/2005302/187232.04e-031.36e-0249
GO:1902903113ThyroidPTCregulation of supramolecular fiber organization202/5968383/187231.16e-171.15e-15202
Page: 1 2 3 4 5 6 7 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
ARHGAP18SNVMissense_Mutationnovelc.1889G>Cp.Gly630Alap.G630AQ8N392protein_codingdeleterious(0.01)probably_damaging(0.936)TCGA-3C-AALI-01Breastbreast invasive carcinomaFemale<65I/IIUnspecificPoly EComplete Response
ARHGAP18SNVMissense_Mutationrs775517266c.1027N>Tp.Pro343Serp.P343SQ8N392protein_codingdeleterious(0.03)probably_damaging(0.989)TCGA-A2-A0EW-01Breastbreast invasive carcinomaFemale<65III/IVChemotherapyadriamycinPD
ARHGAP18SNVMissense_Mutationc.1342N>Cp.Asp448Hisp.D448HQ8N392protein_codingdeleterious(0)benign(0.158)TCGA-A2-A25E-01Breastbreast invasive carcinomaFemale<65III/IVChemotherapycytoxanPD
ARHGAP18SNVMissense_Mutationc.556C>Gp.Pro186Alap.P186AQ8N392protein_codingtolerated(0.16)benign(0.007)TCGA-AC-A23H-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownPD
ARHGAP18SNVMissense_Mutationrs370593148c.769G>Ap.Asp257Asnp.D257NQ8N392protein_codingtolerated(0.17)benign(0.001)TCGA-AN-A046-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownSD
ARHGAP18SNVMissense_Mutationc.29N>Cp.Val10Alap.V10AQ8N392protein_codingdeleterious(0)benign(0.138)TCGA-EW-A1IZ-01Breastbreast invasive carcinomaFemale<65III/IVChemotherapytaxotereSD
ARHGAP18SNVMissense_Mutationnovelc.997N>Cp.Asp333Hisp.D333HQ8N392protein_codingdeleterious(0)probably_damaging(1)TCGA-C5-A8XK-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinSD
ARHGAP18SNVMissense_Mutationc.375G>Tp.Glu125Aspp.E125DQ8N392protein_codingtolerated(0.63)benign(0.003)TCGA-WL-A834-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapypaclitaxelSD
ARHGAP18SNVMissense_Mutationc.1562N>Gp.Leu521Argp.L521RQ8N392protein_codingdeleterious(0)benign(0.196)TCGA-A6-2672-01Colorectumcolon adenocarcinomaFemale>=65III/IVUnknownUnknownSD
ARHGAP18SNVMissense_Mutationc.1208N>Cp.Leu403Prop.L403PQ8N392protein_codingdeleterious(0)probably_damaging(1)TCGA-AD-6895-01Colorectumcolon adenocarcinomaMale>=65III/IVUnknownUnknownSD
Page: 1 2 3 4 5 6 7 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1